and the with and building over to two the we addition signed two process, off an we Thank CX proof-of-concepts the within industry. in collaborations strengths two Dyadic the you, platform long-term X multiple new company. particular, continue Ping. is to we've Good announced on the multiple biotech awareness for already past the pharmaceutical are fully-funded this and value weeks, in research pharma first In of applications creation. In a excellent potential and achieved with further XXXX many start significant to shareholder evening, reinforcing welcome. accomplishments driving fronts, To globally everyone, and make momentum leading new quarter progress ultimately partnerships our this year.
Our pipeline opportunities. licensing and very developments potential we and continues are exploring to numerous be active
to companies. cash sheet, have biotechnology and our position and significant we the both flexibility a with on large Importantly, pharmaceutical balance financial with small partner
an Limited. Luina I'll India two Institute agreement Serum Bio Alphazyme, Research the first and collaboration companies in the on discuss we announced announced followed and partnerships, by LLC; move then new with the our of collaborations. commercialization yesterday, Serum an these update Yesterday, to pharma Private our of research finally, recently with collaborations on now Let's ongoing some developments. exciting announced
manufacturing the as a therapeutic agreement proteins fungal system Dyadic's platform using products. and a expression vaccines Our recombinant biologic CX for covers commercialization of potential commercial development and production
proteins of this fully has certain date development are for vaccines royalties commercially grant XX of which express from and from bear the Under develop to of biologics Dyadic X and work to agreement efforts demonstrate goods. CX technology. developing milestone upto Serum, This Serum speed each XX Dyadic's XX the cost and biologics undertake recombinant and and anticipates return and X the delivering in lowest to of cost it's are for Serum proud Dyadic's sublicense proteins of option collaboration for terms the Serum Serum calls passed first than requisite collaboration, of manufacturing expressed the cost-effective CX potential to has sale. XX and protein-based the agreed technology antibodies, funding, years it's globally. platform obtain development of for monoclonal as the a because We choice the for The proteins research for exclusive a years track-record criteria from proven will CX commercial expressed best commercialize of which proteins; of to applying as of commercialization by to commercial vaccines, and required a the has collaboration. in more with to further the the an payments, CX
We and will and also research required conduct necessary clinical trials. the pre-chemical
two X one including size Tanabe already four deals, previously to Indian drugs FDA announced the vaccines other expression of research marketing XXXX, collaborations first Pharma animal proof-of-concept achieved In applications addition, the Israel of USA Structural company, the CX our of Genomics Serum drugs and U.S. express is plus Oxford; and of IIBR, part we or three gene and a the Top and Top the Centre top-tier quarter to pharmaceutical The to companies Sanofi-Aventis, in we Biotechnology. use SGC, the regulatory in the academic Dyadic including file another and vaccines will institutions, to health. Biological also companies, collaboration signed Consortium, pharmaceutical Institute new human from Molecular required XXXX, allow and which XX chosen two Research, These agreements, platform. Mitsubishi small-to-medium for what collaboration commercialization produced biologic the with CX with XX addition University In of both signed for are Fraunhofer agencies
organization pharmaceutical have the part of companies In to treatment past global express XX In quarter also mentioned years a contract an contract one two Bio, agreement favorably further more one sub-licensing and of with the into growth XX royalties opportunities the weeks, two the trends. in agreement Bio us Australian-based both commercialize In contract has with with than various April companion Dyadic's Luina sub-licensing the a has where be Luina already with of for cases, into to of this equity will development targeted XXXX. platform starting manufacturing added and working animals. we CX prevention to for the and experience. and us we signed stakes expand develop in manufacturing a addition, use agreement. for entered decided number ailments second receive align as will additional protein of and products XX On earlier well products as drug we of Top
CX the of of this also has a human XX% clinical within small products net gene new percentage non-sales ownership biological a Asia. provides revenue for Dyadic's well which Luina proprietary veterinary services sub-licensing Phase part for will Pty receive incorporate a company, earn Dyadic States, manufacturing and both, will both, and agreement, United joint royalties of in suite, trials, expression Australia, platform. commercial with comprehensive Novovet drugs on molecule Bio industry As Dyadic for sales III clients and the Europe experience extensive equity Phase a working and as to I and venture Limited; stake in
a tools Upon a reagents When project medicines and required health to to track-record decades drugs premium to enzymes As as vaccines of resources market to was Alphazyme platform for royalty pets. protein continue year. of Alphazyme which future founded products Alphazyme, the partner low industrial experts expression opportunity such of in successful to of making transfer funded biologic vaccine, for expertise fast sales the can demonstrates success production. will the to believe have potential animal production licensing range animal the in it's and to reaction and sooner scale. in broad to are goal market it's from medicines that business is development manufacturing development they into but diagnostic of be from not for CX this produce by detection pet-ownership speed they Dyadic's measure, custom how developing to agent. applying critical as or sub-licensing net the XXXX. DNA chemical believe is a market the commercializing products manufacturing rights enzyme to Enzymes intermediate of as agreement in molecular to the animal a DuPont Therefore production Alphazyme greater next in further will CX May percentage is On we focused therapeutic need more an new constraint go for standard-of-living turn, We be process certain catalyze the that This receive for enzymes into biological globally, tools clinical be to a required XXXX, turned CX and of used sales. acid proprietary applied. be Alphazyme of on technology, a Dyadic a in may revenue a volume high to entered purpose and have platform or only too molecular and we the biology and detect, we enzyme produced cost potential world's human cost so the utilize by example up enzymes to RNA. their applications lower large-scale our than a Alphazyme, LLC to nucleic as our more quantities or more early ability sub-licensing primarily sold industrial of CX vaccines CX approaching a royalties on industry the the for X, used will that into sub-licensing drugs. of internal with accessible people The interest volumes. offers anticipates of pharmaceutical the at and them trials. of with produce X.X% proof-of-concept milestone combining and to and agreement CX This a potential as a were health has that payments, don't with products drive the for rise produced in maximum start and the see optimizing the Dyadic's because molecular investment agreement development pets. We CX In an their deal. research produced unlock gene and the
to have With more to have anticipate we discussions world. apply we of under in be uncovering more opportunities the NDAs, and we number able XXX and the scientific which continue than CX biopharmaceutical may
an receive both meaningful we to believe and interest shareholder upfront these we the if deals, Alphazyme certainly our value and be long-standing fee. access provide and Bio for equity in cash upside received We Luina create shareholders. greater larger term of an the future. upfront payments deals With we But will expect with ultimately believe what as cash us do a us in companies good and potentially can that partners for will a we
started Next, on the be an higher several that of providing, the we update collaborations. can provide The collaboration will our results be research have proteins XXXX; in October levels to significantly will achieved. initially Sanofi our to-date continue already you I with we in for expression we have and project with believe were the exceeded and levels progress achieved levels we Sanofi. targeted ongoing and expression The encouraged Sanofi-Aventis target
expectations expression that positive We the during conference results these monthly going stated grams calls receive to XX.X library data and for or per expanded initially is Overall, CX expanding demonstrated leading we've stability the the expression research lead project, feedback well with we'll antigen improvements development, license Schmallenberg the to of few we them of the with Tanabe now protein continue updates as believe FC analysis and begin was Mitsubishi I'm With demonstrated target an move continued license the Mitsubishi Mitsubishi universal and level In one now of protein. program, express times during target in this this program X made of or human level. ZAPI Tanabe; XX turn target have we've an double Further, platform protease and If expressed see further of success CX presented we expression CX commercializing Mitsubishi previously Sanofi. eventual and research now against per an protein we meets promising functional hope SBV X grams bimonthly of cell of take level. we the with proteins. for expression this that high of able to again greater protein to reaching are trials conduct you improvement to per specific characterization to additional antigen the this expressed and have hopeful virus against towards goal day. We this that this demonstrated the product. scientific are expression delivering CX to our X.X whole very related indicated to research productivity in pleased to expression SBV. will respect liter initial the steps this antigen CX stated and of can an respect to further fusion There high clinical preclinical a now levels initially the a one collaboration are and that to to already level share to liter to with sample opportunity proteins progress. continue expressed and times proprietary funding have agreement collaboration by and using Mitsubishi's very and we to will times it gene antigen, Sanofi. ongoing a our CX the the sent Pharma a calls expressed
on We is to PCT expanded progress for to downstream glycol-engineering supply. impart provisional AAV CX and further vectors, CX human the research development adeno-associated short from filing We and certolizumab. in for In a purification demand summary, a significant and CX make property programs platform additional our project glycosylation expressed further CX gene progress in new which made pharmaceutical making process CX We a potential in glycoproteins. explore in continue in by high gene application patent our Produced potential months to potential was product, CX expression platform few the strengthen are published. thermophila progress initiated to a produce therapy Vaccine CX, and as reinforce the intellectual past widely drug application a internal applying products demonstrated, to Flu CX of to and develop the are including reportedly virus of Production titled, a Myceliophthora used expression and have animal/human, to We've vaccine, industrially-proven Dyadic globally power biomanufacturing. developing biologic gene of
financial these active an have of pipeline and flexibility on to to continue execute we discussions significant forward, Going opportunities.
of other continue large are data and programs various potentially with forms and and progress in pharmaceutical of We make. stages research are companies and collaborations have negotiations for like biotech small proof-of-concept and who to the ourselves encouraged we by
creating Our and payments equity the stakes, multi-pronged, and agreements approach these for from potential royalties. arrangements and access to these including milestone value ownership fees, shareholders it's is for upfront Dyadic licensing
with BDI interest the and Our share future Bio, Bio Biotech, in Alphazyme Luina to equity our potential and provide Dyadic sub-license success. VLP
and have the investor pharma, biotech made meetings conferences, in been Our governmental year management and team progress we this throughout various XXXX and agencies. have during and I showcasing and scientific with presenting industry the and CX with
communication in efforts. will remain active We our
looking and sector this be XX, at New Beverly members Conference, NASDAQ conferences visibility bell Annual you XX investor industry in We and NASDAQ believe for XXXX D.C. meeting Line our to team in Washington City at BIO NIMBLE our XX to also in be San with XXXX & of ringing expands management most board in our there. in and further will the Healthcare we ceremony June On forward our such Conference that at Francisco, uplifting and FBR will and in as investors. B. June to Hills, We Philadelphia Riley upcoming May Cell are in Development Engineering and York
detail any York. in meet to investors will keep financial you our New to will over plans and time to with aside set Accounting the for call results. Chief Officer turn our I now to We Rawson, discuss posted Ping
